NY-CERTIK
7.4.2022 14:02:13 CEST | Business Wire | Press release
CertiK , the leading global Web3, and blockchain security firm headquartered in New York, today announced the completion of an oversubscribed $88 million Series B3 financing round. This investment is led by Insight Partners, Tiger Global, and Advent International, with participation from Goldman Sachs and existing investors such as Sequoia and Lightspeed Venture Partners. This latest funding now brings CertiK’s valuation to $2 billion in just 3 months since its last round of funding. This is the fourth round of capital raised by CertiK in the past nine months, altogether totaling $230 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220407005208/en/
Blockchain security continues to see strong demand, which has led to substantial growth at CertiK as the leader in the category. Following a substantial loss of $1.3 billion in cryptocurrency in 2021, the year 2022 is already continuing that trend, with cryptocurrency losses predicted to be much higher than last year. Within the last three months, the crypto industry witnessed over $1 billion in cryptocurrency losses due to four major bridge attacks (Ronin Network , Wormhole , Qubit Finance , and Meter.io ), as well as various flash loan attacks; both types of attacks of which seem to be trending this year.
CertiK’s mission is to secure the Web3 world. It delivers on this mission through an end-to-end set of security services, providing clients with a one-stop shop for all their security needs. To date, CertiK has protected over $300 billion worth of crypto assets for well over 3,200 enterprise clients. CertiK’s auditing service provides pre-deployment auditing and formal verification for smart contracts, blockchain protocols, and Web3 apps, while Skynet provides on-chain 24/7 active monitoring of security threats. CertiK also recently launched its Know Your Customer (“KYC”) and fraud investigation service this year. CertiK believes KYC is the missing link in most competitive offers for helping prevent malicious intent i.e., rug-pulls, by owners of a project. Overall, CertiK’s leaderboard enables transparency for its community and builds both trust and visibility for the projects that are listed there.
CertiK’s products and services continue to show strong demand, supporting an incredible growth of revenue for the company. For the year 2021, CertiK saw its revenue surge 12x, while its profits surged by 3,000x. Even with the temporary downturn in the crypto market, CertiK’s 2022 Q1, Year-over-Year Web3 security revenue grew by 4x. According to CoinMarketCap data, CertiK serves 60% of all listed blockchain projects that use third-party security audit services.
CertiK’s leadership and tremendous growth have already been widely recognized by the industry. In March 2022, CertiK received awards for the CB Insights Blockchain 50 award - listed as the only blockchain security firm, and the Globee Awards - Cybersecurity Global Excellence Award.
“CertiK is a mission-critical blockchain cybersecurity platform in a massive market and has already become a clear leader in the industry with a high-quality product that provides all-round security for blockchain, smart contracts, and Web3,” said Steve Ward, Managing Director at Insight Partners. “We look forward to partnering with CertiK’s best in class founding team, complete with a team of leading crypto security thought leaders as they continue to grow and Scale-Up.”
“We are excited to invest in CertiK as a leader in developing critically needed cybersecurity solutions for the Web3/DeFi market,” said Eric Noeth, Partner at Advent International. “The decentralized Internet that runs on the blockchain has experienced high levels of security breaches and is in dire need of the kind of effective solutions that CertiK provides. We look forward to partnering with the CertiK team as it continues its tremendous momentum in making blockchains safer and more performant while also providing consumers with much-needed visibility into security considerations across new and existing projects.”
“Goldman Sachs is excited to be an investor in CertiK, a leading security platform for the blockchain and Web3 ecosystem," said Oli Harris, Managing Director, Goldman Sachs. "As we see continued growth in use cases and assets on decentralized applications the solutions being built by CertiK will be integral to securing the ecosystem, helping to accelerate innovation and adoption of these novel technologies.”
This new round of funding, coupled with revenue generated from KYC, Skynet, and Security Leaderboard services, will be used for the development and operation of more innovative and data-driven security products. “Given increasing trends in rug-pulls, we now see KYC playing an important role in Web3 security,” said CertiK Founder and CEO, Ronghui Gu. “KYC, together with Smart contract auditing and 24/7 monitoring of threats, will further strengthen our offer around end-to-end Web3 security services.”
CertiK continues to hire top-tier product and development talent to help deliver on its end-to-end product strategy. CertiK recently invested in the hire of Kevin Liu, CertiK’s Chief Product Officer. Mr. Liu is an experienced product and engineering leader, with over 20 years of global experience in the technology industry, with a focus on media and telecoms. Before CertiK, Kevin was a founding member of FreeWheel (a Comcast company) where he held various leadership positions, including VP of Product and VP of Engineering. He also served as General Manager, China, and Chief Technology Officer (CTO) of ads, at iflix. As CPO at CertiK, Kevin will be responsible for leading product strategy across the company, building the groundwork for initiatives in securing blockchain applications, and providing insights for the community, project owners, and other participants.
About CertiK
CertiK’s mission is to secure the Web3 world. Starting with blockchain, CertiK applies cutting-edge innovations from academia into Enterprise, enabling mission-critical applications to be built with security and correctness. Headquartered in New York City, CertiK was founded by computer science professors Ronghui Gu and Zhong Shao. CertiK is backed by industry leaders, including Insight Partners, Tiger Global, Sequoia, Coatue Management, Advent International, Goldman Sachs, Lightspeed, Hillhouse Capital, Binance, Coinbase Ventures, and more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005208/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
